

# Company Heartbeats

**Swiss companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
31 Jan 25	Novartis	Annual report	CHF 93.44	Call	<a href="#">S3BUCU</a>	20 Jun 25	15.86	98.00	0.11	<a href="#">Calls on Novartis</a>
				Put	<a href="#">BSLUCU</a>	20 Jun 25	11.65	90.00	0.23	<a href="#">Puts on Novartis</a>
03 Feb 25	Julius Baer	Annual report	CHF 64.12	Call	<a href="#">BKASDU</a>	20 Jun 25	10.90	68.00	0.20	<a href="#">Calls on Julius Baer</a>
05 Feb 25	Daetwyler	Annual report	CHF 138.60	Call	<a href="#">BSJU1U</a>	20 Jun 25	8.06	150.00	0.11	<a href="#">Calls on Daetwyler</a>
07 Feb 25	Ems	Annual report	CHF 643.50	Call	<a href="#">UPASYU</a>	20 Jun 25	8.94	700.00	0.06	<a href="#">Calls on Ems</a>
11 Feb 25	AMS	Annual report	CHF 6.98	Call	<a href="#">BT5SVU</a>	20 Jun 25	3.13	7.50	0.58	<a href="#">Calls on AMS</a>
11 Feb 25	SGS	Annual report	CHF 89.12	Call	<a href="#">SJBW2U</a>	20 Jun 25	12.03	95.00	0.10	<a href="#">Calls on SGS</a>
				Put	<a href="#">BSGU2U</a>	20 Jun 25	8.51	85.00	0.22	<a href="#">Puts on SGS</a>
12 Feb 25	Schindler	Annual report	CHF 259.40	Call	<a href="#">SXBUFU</a>	20 Jun 25	8.35	270.00	0.23	<a href="#">Calls on Schindler</a>
13 Feb 25	Swisscom	Annual report	CHF 519.00	Call	<a href="#">UJBS3U</a>	20 Jun 25	20.76	540.00	0.07	<a href="#">Calls on Swisscom</a>
				Put	<a href="#">BSHUPU</a>	20 Jun 25	11.94	500.00	0.20	<a href="#">Puts on Swisscom</a>
13 Feb 25	Nestle	Annual report	CHF 78.28	Call	<a href="#">SBJU5U</a>	20 Jun 25	16.70	82.00	0.10	<a href="#">Calls on Nestle</a>
				Put	<a href="#">BSHUQU</a>	20 Jun 25	11.26	75.00	0.19	<a href="#">Puts on Nestle</a>
14 Feb 25	DKSH	Annual report	CHF 71.70	Call	<a href="#">SLBU4U</a>	20 Jun 25	11.55	75.00	0.09	<a href="#">Calls on DKSH</a>
18 Feb 25	Temenos Group	Annual report	CHF 77.10	Call	<a href="#">1TEMHU</a>	20 Jun 25	5.80	80.00	0.25	<a href="#">Calls on Temenos Group</a>
18 Feb 25	OC Oerlikon	Annual report	CHF 3.56	Call	<a href="#">B1VSKU</a>	20 Jun 25	6.92	3.80	0.09	<a href="#">Calls on OC Oerlikon</a>

Source: Refinitiv, UBS.

As of: 30 Jan 25. All prices are indicative.

# Company Heartbeats

**International companies** - Position yourself with UBS Warrants for upcoming financial results

Company Heartbeats regularly lists companies that will soon present their financial results and for which UBS is offering suitable Warrants. The Warrants are listed on the SIX Structured Products Exchange and tradable on every trading day under normal market conditions. Please consider the disclaimer at the end of this document.

Date	Company	Publication	Share price	Suitable Warrants						
				Type	SIX symbol	Expiry	Leverage	Strike	Ask price	More Warrants
04 Feb 25	Alphabet	Annual report	USD 197.18	Call	<a href="#">BKKSPU</a>	20 Jun 25	7.21	205.00	0.67	<a href="#">Calls on Alphabet</a>
04 Feb 25	AMD	Annual report	USD 117.35	Call	<a href="#">B4DSOU</a>	20 Jun 25	5.38	130.00	0.48	<a href="#">Calls on AMD</a>
05 Feb 25	Paypal	Annual report	USD 88.76	Call	<a href="#">BS6URU</a>	20 Jun 25	6.80	95.00	0.12	<a href="#">Calls on Paypal</a>
05 Feb 25	Alibaba	Semi-annual report	USD 96.72	Call	<a href="#">SBUXTU</a>	20 Jun 25	5.70	100.00	0.45	<a href="#">Calls on Alibaba</a>
06 Feb 25	Amazon	Annual report	USD 237.07	Call	<a href="#">BC9SDU</a>	20 Jun 25	7.56	245.00	0.32	<a href="#">Calls on Amazon</a>
06 Feb 25	Eli Lilly	Annual report	USD 804.08	Call	<a href="#">BMPS6U</a>	20 Jun 25	7.40	850.00	0.50	<a href="#">Calls on Eli Lilly</a>
12 Feb 25	Barrick Gold	Annual report	USD 15.96	Call	<a href="#">3GOLNU</a>	20 Jun 25	7.02	17.00	0.20	<a href="#">Calls on Barrick Gold</a>
13 Feb 25	Commerzbank	Annual report	EUR 18.49	Call	<a href="#">B7OS9U</a>	20 Jun 25	10.21	20.00	0.17	<a href="#">Calls on Commerzbank</a>
20 Feb 25	Moderna	Annual report	USD 40.72	Call	<a href="#">BN6SDU</a>	20 Jun 25	3.37	42.00	0.70	<a href="#">Calls on Moderna</a>
26 Feb 25	NVIDIA	Annual report	USD 123.70	Call	<a href="#">S3BUMU</a>	20 Jun 25	4.46	135.00	1.33	<a href="#">Calls on NVIDIA</a>
05 Mar 25	Bayer	Annual report	EUR 21.54	Call	<a href="#">B93SSU</a>	20 Jun 25	5.98	22.50	0.18	<a href="#">Calls on Bayer</a>
06 Mar 25	Lufthansa	Annual report	EUR 6.18	Call	<a href="#">SCBUCU</a>	20 Jun 25	6.96	6.50	0.08	<a href="#">Calls on Lufthansa</a>

Source: Refinitiv, UBS.

As of: 30 Jan 25. All prices are indicative.

## Disclaimer

This material has been prepared by UBS AG or one of its affiliates ("UBS"). This material is only intended for the distribution permitted under the applicable law. It has not been prepared for the needs of a specific recipient. It is only published for information purposes and does not constitute an offer or an invitation to purchase or sell securities or associated financial instruments ("Instruments"). UBS accepts no liability (either expressly or tacitly) for the completeness or reliability of the information contained in this document, except for the information on UBS AG and its affiliates. The information should not be regarded by the recipients as a substitute for their own judgment. All the opinions contained herein may change without prior notice and contradict the opinions of other business areas of UBS due to the application of different assumptions and criteria. UBS is not obliged to keep the information up to date. UBS, its executives, employees or clients may have or have had a participation in the Instruments and may conclude transactions with them at any time. UBS may maintain or have maintained a relationship with the entities specified in this information. Neither UBS nor its affiliates, executives or employees are liable for losses resulting from the use of this information.

**Structured derivatives do not constitute participation in collective investment schemes. For this reason they do not require approval from the Swiss Financial Market Supervisory Authority (FINMA). As a result, investors are not entitled to the specific investor protection provided by the Swiss Collective Investment Schemes Act (CISA).**

Structured products are complex and involve a high risk. The intrinsic value of the investment instruments depends not only on the performance of the underlying asset, but also on the issuer's creditworthiness (credit risk), which can change over the duration of the product. In relation to any securities, currencies, financial instruments or other assets underlying a transaction to which this material relates, the values may fall as well as rise and past performance is not an indication of future performance. Before entering into any transaction, you should consult your own legal, supervisory, tax, financial and accounting advisors as you consider necessary. You should also make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) at your own discretion and based on your consultation with advisors as you consider necessary. Unless expressly agreed otherwise in writing, UBS does not act as financial advisor or fiduciary in any transaction. The terms and conditions of an investment are subject solely to the detailed provisions, including risk considerations, contained in the relevant product documentation. The product documentation, i.e. the prospectus and the Key Information Document (KID), can be obtained from the website [keyinvest.ch.en.ubs.com](http://keyinvest.ch.en.ubs.com), by entering the relevant security / ISIN. Before you invest in a product, please read the current prospectus and the Key Information Document (KID) carefully and thoroughly. UBS makes no representations or warranties with regard to any information contained herein, which originates from independent sources. This publication may not be copied or reproduced without UBS's prior written permission.

Not for distribution in the United States or to US persons. © UBS 2025. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS. UBS prohibits the forwarding of this information without the approval of UBS.

## Contact

[keyinvest@ubs.com](mailto:keyinvest@ubs.com)

+41 44 239 76 76\*

[ubs.com/keyinvest](http://ubs.com/keyinvest)

\*Please note that calls to numbers marked with \* may be recorded. When you call these numbers, we assume that you consent to this practice.